Results 141 to 150 of about 153,414 (353)
Dynamics of postnatal bone development and epiphyseal synostosis in the caprine autopod
Abstract Background Bones develop to structurally balance strength and mobility. Bone developmental dynamics are influenced by whether an animal is ambulatory at birth. Precocial species, which are ambulatory at birth, develop advanced skeletal maturity in utero and experience postnatal development under mechanical loading.
Christopher J. Panebianco +8 more
wiley +1 more source
Earnings Management around Seasoned Equity Offerings: Evidence from Non-Investment Accruals.
Loreta Rapushi
openalex +1 more source
The Changing Landscape of Accrual Accounting
Robert M. Bushman +2 more
openalex +1 more source
Cilostazol in patients with heart failure and preserved ejection fraction—The CLIP‐HFpEF trial
• Cilostazol is an oral PDE‐3 inhibitor that may have advantageous effects in heart failure with preserved ejection fraction (HFpEF). • Cilostazol significantly improved short‐term heart failure‐related health status scores (KCCQ‐12) and NT‐proBNP levels when compared to placebo.
Norman Aiad +9 more
wiley +1 more source
Premises and Purpose of the study: Despite anticoagulant therapy, in primary antiphospholipid syndrome (PAPS), a higher rate of recurrent events occurs, leading to potentially accrued damage with a negative impact on quality of life.
doaj +1 more source
Cash to Accruals Accounting in British Central Government; a Journey Through Time
John Richard Edwards
openalex +1 more source
Concentration Effects of Inorganic Nitrogen on Biomass Accrual of Periphyton in a Subalpine Stream, Colorado Front Range [PDF]
Dale W. Toetz, Mark E. Payton
openalex +1 more source
Abstract Aims The EMAIL‐HF trial aims to evaluate whether a digital guideline implementation strategy can increase and accelerate initiation of sodium‐glucose co‐transporter 2 (SGLT2) inhibitors in patients with heart failure (HF). Methods and results EMAIL‐HF is a pragmatic, registry‐based, randomized controlled trial including patients with a ...
Mariam Elmegaard +21 more
wiley +1 more source
We investigated cardiometabolic outcomes in patients treated with dapagliflozin 10 mg once daily or placebo after acute myocardial infarction according to LVEF at randomisation in the registry‐based, randomised DAPA‐MI trial. Regardless of baseline LVEF, dapagliflozin resulted in significant cardiometabolic benefits versus placebo, suggesting that ...
David Erlinge +19 more
wiley +1 more source

